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The pattern of deposition of inhaled medications is non-uniform in people with CF. Deposition follows tidal ventilation, so inhalation in sitting tends to under-dose the apices. One theory is that inhalation while in alternate side lying (ASL) would improve homogeneity of deposition by preferentially dosing each lung (including the apex) when it is dependent. Before testing this theory, we sought to determine whether there was any slowing of delivery time with the ASL strategy. Method: 24 adults (mean±SD age 30±9 y, 13F) with stable CF lung disease (FEV1% pred 55±34) inhaled 4 mL of normal saline via an LC Star ® nebuliser twice within 24 hours. During the first inhalation, participants were randomised to sit upright throughout the nebulisation period (SIT) or to alternate between left and right side lying at each minute during the nebulisation period (ASL). Participants used the opposite positioning regimen during their second inhalation. The nebuliser was stopped and weighed each minute to determine output until the residual volume (0.5 mL) was reached.
Results:
The delivery time did not significantly differ between SIT (18.54±3.80min) and ASL (17.96±3.53min), a difference of 0.58 min (95%CI 1.40 to −0.24). There was no significant correlation between delivery time and FEV1, FVC or height. In ASL, increasing the time between turns to 2min did not significantly affect the dose delivered on each side, however turning each 3min resulted in less uniformity (mean ratio 1.32, 95%CI 1.24 to 1.40). Discussion: ASL during inhalation therapy does not prolong delivery time. We are now investigating the effect of ASL on uniformity of deposition with radioaerosol scans. This 4 month randomised cross-over trial compared taking Pulmozyme at 4pm, with taking it immediately following the evening session of chest physiotherapy. The primary outcome was FEF25 with secondary outcomes being FEV1 and subjective feedback to assess whether there were any side effects from taking Pulmozyme late at night. A large number of subjects could not be recruited or had to be withdrawn from the study due to increased respiratory symptoms. The total number of patients who completed the study was 5, with a mean age of 11 years old. The results of this study did not show any significant differences between the two timing of Pulmozyme with p = 0.557 for FEF25 and p = 0.868 for FEV1. Therefore no conclusions as to which of the two different timings of Pulmozyme is the most effective at reducing airflow obstruction can be drawn from this study. There were no reported increase in overnight symptoms from any subjects from taking Pulmozyme in the evening, so it could be concluded that Pulmozyme is safe to administer at that time.
There have been several short term studies investigating this research question. This study attempted to carry out a longer term study with a similar study design as previous shorter term research. However the difficulty in subject recruitment and the high drop out rates reported here have previously also been reported by investigators attempting a longer term study with this design. The authors conclude that this type of study design is not appropriate for a longer term investigation to answer this research question. All sputum samples were collected from patients and rheological measurements undertaken within 24 hours. All measurements were taken at a temperature of 25 o C, using an Anton Paar Physica MCR 501 rheometer. All samples were equilibriated in the rheometer for a period of 1 hour before measurements were taken. The intention was to freeze samples when supplied, but data illustrating the complex viscosity of three examples of the mucus, on which measurements were taken immediately, followed by freezing for a period of 4 days, showed that freezing of the mucus can result in significant changes of the gel structure. One example, ETO801763 showed little change in the values of the complex viscosity but another example, ETO801764, showed a considerable decrease, whilst a third example, ETO801765, gave increased values. Data illustrating the complex viscosity of a large number of samples will be presented. Large variations in the values of the complex viscosity were observed, ranging from almost 10 6 mPas to 3000 mPas. Although the overall general pattern of behaviour of the samples is a reduction in the value with increasing frequency of oscillation, there were exceptions to this pattern, where an increase is initially seen in some cases at low levels of oscillation but, in others, a sharp increase is observed at very high levels.
In conclusion, consideration should be paid to the danger of complicating effects of cryo-preservation prior to physical analysis of cystic fibrosis sputum. This data also suggests that components within the sputum generate unpredictable and highly variable rheological data in different patients. Unravelling the biochemical basis of this variability may assist the development of improved therapeutic approaches to the treatment of cystic fibrosis.
